Midatech is an international specialty pharmaceutical company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech is advancing a pipeline of novel clinical and pre-clinical product candidates based on its proprietary drug conjugate and sustained release delivery platforms with a clear focus on the key therapeutic areas of Cancer, Endocrine Disorders such as Diabetes, and Immunotherapy for autoimmune diseases. Midatechâs strategy is to develop its products in-house in rare cancers and with partners in other indications.
Midatech Pharma Group is incorporated in England and Wales, with global headquarters in the United Kingdom and a fully integrated commercial subsidiary based in the United States. Midatechâs ordinary shares are traded on the Alternative Investment Market (AIM) of the London Stock Exchange under the ticker symbol MTPH (ISIN number GB00BRTL9B63). Midatechâs American Depositary Shares trade on the NASDAQ Capital Market in the United States under the symbol MTP (CUSIP No. 59564R203).
Source
